Jennifer Schneider, MD
Ophthalmology · Suffolk, VANPI 1336301837
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $5,997 of the $9,224 with a category attached, or 65.0%. It is spread thinly across 29 manufacturers, the largest accounting for just 20.2%. Among ophthalmology clinicians in VA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 299 payments — averaging $30.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$2K
- AbbVie$2K
- Ocular Therapeutix, Inc.$1K
- Mallinckrodt Hospital Products Inc.$721
- Notal Vision, Inc.$384
- NEW World Medical,inc.$369
- plus $3K from 23 others
What the payments were for
- Speaking & faculty fees$1,99122%
- Food & beverage$5,99765%
- Gifts$360%
- Other$1,20013%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen(2 entities) | 20 | $1,865 |
| AbbVie(2 entities) | 90 | $1,619 |
| Ocular Therapeutix, Inc. | 14 | $1,421 |
| Mallinckrodt Hospital Products Inc. | 37 | $721 |
| Notal Vision, Inc. | 1 | $384 |
| NEW World Medical,inc. | 5 | $369 |
| Biotissue Holdings Inc. | 18 | $330 |
| Alcon | 13 | $273 |
| Sun Pharmaceutical Industries Inc. | 11 | $255 |
| Novartis | 12 | $248 |
| Harrow Eye, LLC | 7 | $210 |
| Aerie Pharmaceuticals, Inc. | 8 | $204 |
| Tarsus Pharmaceuticals, Inc. | 6 | $165 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 7 | $150 |
| Oyster Point Pharma, Inc. | 7 | $144 |
| Bausch & Lomb Americas Inc. | 8 | $142 |
| Carl Zeiss Meditec USA, Inc. | 4 | $106 |
| Rayner Intraocular Lenses Limited | 5 | $102 |
| Sight Sciences, Inc. | 5 | $82 |
| Kala Pharmaceuticals, Inc. | 4 | $78 |
| Eyepoint US, Inc. | 3 | $68 |
| Glaukos Corporation | 3 | $67 |
| Rxsight Inc | 2 | $65 |
| Dompe US, Inc. | 3 | $60 |
| Shire North American Group Inc | 2 | $32 |
| Thea Pharma Inc. | 1 | $21 |
| Apellis Pharmaceuticals, Inc. | 1 | $21 |
| Johnson & Johnson Surgical Vision, Inc. | 1 | $12 |
| Oasis Medical, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$9,224 in reported general payments places this provider in the 90th percentile of 509 ophthalmology providers in Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LumiganBimatoprost | 183 | $109,736 |
| RestasisCyclosporine | 90 | $102,817 |
| CombiganBrimonidine Tartrate/Timolol | 82 | $42,262 |
| Cyclosporine | 46 | $33,654 |
| RocklatanNetarsudil Mesylat/Latanoprost | 64 | $32,964 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 90 | $23,988 |
| Prednisolone Acetate | 330 | $17,383 |
| XiidraLifitegrast | 14 | $16,160 |
| RhopressaNetarsudil Mesylate | 23 | $15,337 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 64 | $14,164 |
| Travoprost | 88 | $11,726 |
| VyzultaLatanoprostene Bunod | 15 | $9,145 |
| Latanoprost | 818 | $8,112 |
| Brimonidine Tartrate | 105 | $5,836 |
| IlevroNepafenac | 12 | $5,742 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLumigan, Restasis, Combigan | $1,619 | $254,815355 claims |
| Aerie Pharmaceuticals, Inc.Rocklatan, Rhopressa | $204 | $48,30187 claims |
| Bausch & Lomb Americas Inc.Xiidra, Vyzulta | $142 | $25,30629 claims |
| AlconSimbrinza | $273 | $23,98890 claims |
| NovartisIlevro | $248 | $5,74212 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate | $150 | $2,41412 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 509 ophthalmology providers in Virginia.
Other ophthalmology in Suffolk
- Ethnie JonesRichmond$2M
- Elizabeth Yeu-LinNorfolk$1.7M
- John SheppardNorfolk$1.1M
- Constance OkekeNorfolk$800K
- Marc OdrichCharlottesville$497K
- Jayakrishna AmbatiCharlottesville$116K
- Thomas JolyNorfolk$95K
- Stephen ScoperNorfolk$88K
- Leonard RappaportPortsmouth$85K
- Soheila RostamiReston$73K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.